Wedbush analysts on Wednesday reiterated Viridian Therapeutics (VRDN) at Outperform rating but trimmed the price target to $31 from $37. Viridian Therapeutics discovers, develops, and commercialises treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug and Elegrobart.The revision in target price follows Amgen's (AMGN) relea...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.